Global Rare Kidney Diseases Market

Report ID : 1414 | Published : 2022-10-19 | Pages: 194 | Format: PDF/EXCEL

The market size of the Global Rare Kidney Diseases Market is predicted to show an 16% CAGR during the forecast period. Kidney diseases have the potential to intensify over time, eventually leading to kidney failure, which is when the kidneys completely stop working. In addition, having one of these diseases can put you at a higher risk for developing another condition, such as cardiovascular disease. At least 150 distinct conditions are classified as rare kidney diseases, and the majority are inherited. The diagnosis and treatment of rare kidney diseases as a group may present overlapping difficulties, even though individual cases of these diseases present unique obstacles. Diagnosis, management, and treatment of inherited kidney disorders are complicated, especially when multisystem complications are present. These diseases can result in numerous physical and mental impairments, lowering life expectancy and reducing the quality of life. In the last two years, the COVID-19 infection severely affected the human lifestyle and approach towards chronic disease treatment. This led to delayed detection of rare kidney diseases and became responsible for the increase in the number of patients.

Several important factors are responsible for the growth of the rare kidney disease market. It is anticipated that the increasing use of next-generation sequencing techniques will improve diagnostic accuracy for rare kidney diseases, aid in elucidating the molecular mechanism of disease, facilitate genetic counselling, and provide opportunities for carrier testing. Renal replacement therapy advancements and increased accessibility allow for more prolonged patient survival, but frequently at the expense of their quality of life. FDA approvals, Government initiatives and funding also contribute to expanding the market for such complicated diseases. In 2021, IgA nephropathy was rare kidney disease, and the FDA approved the first medication to reduce urine protein. The FDA had approved Tarpeyo (budesonide) delayed-release capsules to treat adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression by lowering proteinuria (increased protein levels in the urine).

Multiple factors, including unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and outdated diagnostic classifications that do not reflect underlying pathophysiological mechanisms, have impacted therapeutic advancements in rare kidney diseases. Slow drug approvals and complex studies will also restrain the market's growth.

The Rare Kidney Diseases market is segmented into target indications, type of molecule, and route of administration. Target indication segment includes IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and others. Another segment is a type of molecule, which comprises Small Molecules and biologics. The subsegment biologics include Monoclonal Antibody, Hormone, Recombinant Protein, and Others. The last segment is the route of administration which has Oral, Intravenous, Subcutaneous, and other routes as subsegments.

According to regional analysis, North America will lead the global Rare Kidney Diseases market during the forecast period due to rapid clinical advancement breakthroughs and research for treatments of kidney diseases.

The key market players are GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Rare Kidney Diseases Market Snapshot

Chapter 4. Global Rare Kidney Diseases Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Clinical Trial/Pipeline Analysis

4.8. Competitive Landscape & Market Share Analysis

4.9. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Target Indication Estimates & Trend Analysis

5.1. by Target Indication & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Target Indication:

5.2.1. IgA Nephropathy

5.2.2. Lupus Nephritis

5.2.3. Focal Segmental Glomerular Sclerosis

5.2.4. Membranous Nephropathy

5.2.5. C3 Glomerulopathy

5.2.6. Cystinosis

5.2.7. Dense Deposit Disease

5.2.8. Distal Renal Tubular Acidosis

5.2.9. Fabry Disease

5.2.10. Refractory Gout

5.2.11. Atypical Hemolytic Uremic Syndrome

5.2.12. Others

Chapter 6. Market Segmentation 2: by Type of Molecule Estimates & Trend Analysis

6.1. by Type Of Molecule & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Type of Molecule:

6.2.1. Small Molecules

6.2.2. Biologics

6.2.2.1. Monoclonal Antibody

6.2.2.2. Hormone

6.2.2.3. Recombinant Protein

6.2.2.4. Others

Chapter 7. Market Segmentation 3: by Route of Administration Estimates & Trend Analysis

7.1. by Route Of Administration & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Route Of Administration:

7.2.1. Oral

7.2.2. Intravenous

7.2.3. Subcutaneous

7.2.4. Others

Chapter 8. Rare Kidney Diseases Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2022-2030

8.1.2. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Type Of Molecule, 2022-2030

8.1.3. North America Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2022-2030

8.1.4. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.2. Europe

8.2.1. Europe Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.2.2. Europe Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.2.3. Europe Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2022-2030

8.2.4. Europe Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.3.2. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.3.3. Asia-Pacific Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2022-2030

8.3.4. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

8.4. Latin America

8.4.1. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.4.2. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.4.3. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2022-2030

8.4.4. Latin America Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.5.2. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.5.3. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2022-2030

8.5.4. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. GlaxoSmithKline

9.2.2. Recordati Rare Diseases

9.2.3. Amicus Therapeutics

9.2.4. Calliditas Therapeutics

9.2.5. Alexion Pharmaceuticals (A subsidiary of AstraZeneca)

9.2.6. Travere Therapeutics

9.2.7. Aurinia Pharmaceutical

9.2.8. Advicenne

9.2.9. Protalix Biotherapeutics

9.2.10. AstraZeneca

9.2.11. Chinook Therapeutics

9.2.12. Reata Pharmaceuticals

9.2.13. Roche

9.2.14. Novartis Pharmaceuticals

9.2.15. Merk & co

9.2.16. Apellis Pharmaceuticals

9.2.17. Omeros Corporation

9.2.18. Other Prominent Players

Market Segmentation

Global Rare Kidney Diseases Market, by Target Indication, 2022-2030 (Value US$ Mn)

  • IgA Nephropathy
  • Lupus Nephritis

  • Focal Segmental Glomerular Sclerosis

  • Membranous Nephropathy

  • C3 Glomerulopathy

  • Cystinosis

  • Dense Deposit Disease

  • Distal Renal Tubular Acidosis

  • Fabry Disease

  • Refractory Gout

  • Atypical Hemolytic Uremic Syndrome

  • Others

 

Global Rare Kidney Diseases Market, by Type Of Molecule, 2022-2030 (Value US$ Mn)

  • Small Molecules
  • Biologics
    • Monoclonal Antibody
    • Hormone
    • Recombinant Protein
    • Others

 Global Rare Kidney Diseases Market, by Route Of Administration, 2022-2030 (Value US$ Mn)

  • Oral
  • Intravenous
  • Subcutaneous
  • Others

 Global Rare Kidney Diseases Market, by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 North America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

 Europe Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

 Asia Pacific Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

 Latin America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

 

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Rare Kidney Diseases Market?

CAGR of 16% during a forecast period of 2022-2030.

Our Clients